Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Quality of working life

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44297   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    221 result(s) found for: Quality of working life. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004054-21 Sponsor Protocol Number: CC-5013-DLC-002 Start Date*: 2014-09-26
    Sponsor Name:Celgene Corporation
    Full Title: Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Ch...
    Medical condition: Previously untreated, activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL).
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10012859 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage II LLT
    17.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    17.0 100000004864 10012860 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage III LLT
    17.0 100000004864 10012861 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IE (Completed) CZ (Completed) IT (Completed) PT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003727-10 Sponsor Protocol Number: MO40598 Start Date*: 2019-12-16
    Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003889-14 Sponsor Protocol Number: NLG-LBC7 Start Date*: 2020-04-07
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized...
    Medical condition: Diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004377-84 Sponsor Protocol Number: GO27834 Start Date*: 2013-04-11
    Sponsor Name:Genentech, Inc.
    Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi...
    Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    20.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    20.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004977-38 Sponsor Protocol Number: VERLEN Start Date*: 2021-07-08
    Sponsor Name:LYSARC
    Full Title: Phase II, Open-Label Study evaluating efficacy of Tafasitamab and Lenalinomide associated to Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older
    Medical condition: Frontline DLBCL
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017930-35 Sponsor Protocol Number: AB06002 Start Date*: 2010-06-29
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and ...
    Medical condition: Multiple Myeloma relapsing after one previous line therapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) AT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) ES (Completed) IT (Completed) GR (Completed) HU (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003033-42 Sponsor Protocol Number: EURO-RELAX Start Date*: 2020-01-28
    Sponsor Name:INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE
    Full Title: The impact of deep versus standard muscle relaxation on intra-operative safety during laparoscopic surgery: a multicenter strategy study – EURO RELAX STUDY
    Medical condition: Intra-operative adverse events during laparoscopic surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002864-30 Sponsor Protocol Number: NL73019.018.20 Start Date*: 2020-07-29
    Sponsor Name:Amsterdam UMC, location AMC
    Full Title: Sulodexide for chronic heart failure: a proof of concept, randomized, placebo-controlled study
    Medical condition: Chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002023-21 Sponsor Protocol Number: GO39942 Start Date*: 2018-08-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ...
    Medical condition: Diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019575-29 Sponsor Protocol Number: CLL210Version10 Start Date*: 2011-04-15
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool and Broadgreen University Hospital NHS Trust
    Full Title: Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210)
    Medical condition: Chronic lymphocytic leukaemia / Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    18.0 100000004864 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003488-12 Sponsor Protocol Number: 54659 Start Date*: 2016-08-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe hand eczema. A randomized prospective open-label trial with blinded outcome assessment.
    Medical condition: Hand eczema (HE) is a common condition with a 1-year period prevalence up to 10%. Systemic treatment with alitretinoin is registered for all clinical types of HE. However, it is especially effectiv...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002238-21 Sponsor Protocol Number: EFC12522 Start Date*: 2017-08-31
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone ve...
    Medical condition: Plasma cell myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) LT (Trial now transitioned) BE (Completed) ES (Ongoing) PT (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001141-13 Sponsor Protocol Number: GO40516 Start Date*: 2020-02-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN...
    Medical condition: B-cell non-Hodgkin lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10023768 Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10023769 Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001840-83 Sponsor Protocol Number: SAGA Start Date*: 2022-04-26
    Sponsor Name:University Medical Center Utrecht
    Full Title: Short-course aminoglycosides as adjunctive treatment in adults with sepsis
    Medical condition: Patients admitted with sepsis of unknown origin, suspected urinary origin or suspected abdominal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002190-25 Sponsor Protocol Number: GEM-IBERDARAX Start Date*: 2022-06-09
    Sponsor Name:Fundacion PETHEMA
    Full Title: Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001503-33 Sponsor Protocol Number: 2019PI200 Start Date*: 2021-07-21
    Sponsor Name:CHRU de Nancy
    Full Title: The impact of deep versus standard muscle relaxation on intra-operative safety during laparoscopic surgery: a multicenter strategy study – EURO RELAX STUDY
    Medical condition: Intra-operative adverse events during laparoscopic surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10058468 Laparoscopic surgery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004758-27 Sponsor Protocol Number: IVIGPANSOpen Start Date*: 2020-03-02
    Sponsor Name:Gillberg Neuropsychiatry Centre
    Full Title: Intravenous immunoglobulin (IVIG) treatment in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS): an open-label trial in South-western Sweden
    Medical condition: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsions and...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000312-15 Sponsor Protocol Number: P150902 Start Date*: 2016-08-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy
    Medical condition: Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001097-15 Sponsor Protocol Number: M15-889 Start Date*: 2016-09-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (Venice II)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000877-30 Sponsor Protocol Number: SK0608 Start Date*: 2006-09-08
    Sponsor Name:Reckitt Benckiser Healthcare International
    Full Title: A 6 week, multi centre study to evaluate the efficacy and safety of E45 complete emollient therapy and E45 itch relief cream in the treatment of mild to moderate atopic eczema compared to a patient...
    Medical condition: Atopic Eczema
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA